FSD Pharma Commences Clinical Trial for Alcohol Intoxication Supplement

FSD Pharma Inc., a biopharmaceutical company, announced a partnership with Applied Science and Performance Institute (ASPI) in Tampa, Florida, to conduct a clinical trial named METAL-2. The trial will investigate the safety and efficacy of unbuzzd™, a dietary supplement aimed at reducing alcohol intoxication effects. The study commenced on April 24, 2024, and features a double-blind, placebo-controlled crossover design involving thirty healthy volunteers.

unbuzzd™ contains natural ingredients and vitamins recognized as safe by regulatory standards, potentially enhancing cognition and accelerating alcohol metabolism. This trial is significant for FSD Pharma as it explores the supplement’s ability to counteract acute alcohol intoxication when compared to a placebo.

Mr. Zeeshan Saeed, CEO of FSD Pharma, expressed optimism about the partnership with ASPI and their expertise in supplement trials. He highlighted that the study accentuates FSD Pharma’s focus on pioneering products that address alcohol intoxication.